AU2003226955A1 - Translocation dependent complementation for drug screening - Google Patents

Translocation dependent complementation for drug screening

Info

Publication number
AU2003226955A1
AU2003226955A1 AU2003226955A AU2003226955A AU2003226955A1 AU 2003226955 A1 AU2003226955 A1 AU 2003226955A1 AU 2003226955 A AU2003226955 A AU 2003226955A AU 2003226955 A AU2003226955 A AU 2003226955A AU 2003226955 A1 AU2003226955 A1 AU 2003226955A1
Authority
AU
Australia
Prior art keywords
drug screening
translocation
dependent complementation
complementation
translocation dependent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003226955A
Inventor
Soren Weis Dahl
Grith Hagel
Soren Jensby Nielsen
Morten Praestegaard
Bernard Robert Terry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioImage AS
Original Assignee
BioImage AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2002/000882 external-priority patent/WO2003089464A1/en
Application filed by BioImage AS filed Critical BioImage AS
Publication of AU2003226955A1 publication Critical patent/AU2003226955A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
    • G01N2333/43595—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from coelenteratae, e.g. medusae
AU2003226955A 2002-04-19 2003-04-22 Translocation dependent complementation for drug screening Abandoned AU2003226955A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
DKPA200200591 2002-04-19
DKPA200200591 2002-04-19
DKPA200200896 2002-06-13
DKPA200200896 2002-06-13
DKPA200201029 2002-07-01
DKPA200201029 2002-07-01
PCT/DK2002/000882 WO2003089464A1 (en) 2002-04-19 2002-12-19 Two green fluorescent protein fragments and their use in a method for detecting protein - protein interactions
AU2002358466 2002-12-19
PCT/DK2003/000266 WO2003089627A1 (en) 2002-04-19 2003-04-22 Translocation dependent complementation for drug screening

Publications (1)

Publication Number Publication Date
AU2003226955A1 true AU2003226955A1 (en) 2003-11-03

Family

ID=29255411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003226955A Abandoned AU2003226955A1 (en) 2002-04-19 2003-04-22 Translocation dependent complementation for drug screening

Country Status (4)

Country Link
EP (1) EP1509596A1 (en)
JP (1) JP2005527210A (en)
AU (1) AU2003226955A1 (en)
WO (1) WO2003089627A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166424B2 (en) * 1998-02-02 2007-01-23 Odyssey Thera Inc. Fragments of fluorescent proteins for protein fragment complementation assays
EP1692156B1 (en) * 2003-10-24 2012-12-26 Los Alamos National Security, LLC Self-assembling split-fluorescent protein systems
GB0327143D0 (en) * 2003-11-21 2003-12-24 Univ Belfast Assay
US8586294B2 (en) * 2004-05-18 2013-11-19 The Board Of Trustees Of The Leland Stanford Junior University Detection of protein translocation by beta-galactosidase reporter fragment complementation
EP1687640A2 (en) * 2004-05-19 2006-08-09 Kobenhavns Universitet Adam12, a novel marker for abnormal cell function
US20060040338A1 (en) * 2004-08-18 2006-02-23 Odyssey Thera, Inc. Pharmacological profiling of drugs with cell-based assays
EP1674478A1 (en) * 2004-12-22 2006-06-28 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Fusion proteins and method for determining protein-protein-interactions in living cells and cell lysates, nucleic acids encoding these fusion proteins, as well as vectors and kits containing these
JP2008546411A (en) * 2005-06-21 2008-12-25 ディスカヴァーエックス インコーポレイテッド Fission index assay
GB201503133D0 (en) 2015-02-24 2015-04-08 Ucl Business Plc And Syncona Partners Llp Chimeric protein

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4906100A (en) * 1999-05-27 2000-12-18 Merck Frosst Canada & Co. Assays for caspase activity using green fluorescent proteins
WO2001087919A2 (en) * 2000-05-12 2001-11-22 Yale University Methods of detecting interactions between proteins, peptides or libraries thereof using fusion proteins

Also Published As

Publication number Publication date
EP1509596A1 (en) 2005-03-02
WO2003089627A1 (en) 2003-10-30
JP2005527210A (en) 2005-09-15

Similar Documents

Publication Publication Date Title
AU2003281427A1 (en) Advertising trays for security screening
AU2003235198A1 (en) Automatic tablet packing apparatus with separated hoppers
AU2003262907A1 (en) Automatic prescription drug dispenser
AU2003901813A0 (en) Pharmaceutical derivatives
AU2002238874A1 (en) Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
AU2003250372A1 (en) Pharmaceutical composition
AU2002214006A1 (en) Drugs for diabetes
AU2003221699A1 (en) Pharmaceutical preparation for taste masking
AU2003212822A1 (en) Methods for determining drug responsiveness
AU2003226955A1 (en) Translocation dependent complementation for drug screening
AU2003208673A1 (en) Pacifier for administering flavour substances
AU2003293253A1 (en) Selecting electrotherapy dosage
AU2003236720A1 (en) Substituted diaminopyrimidines
AU2003267705A1 (en) Multi-layered collimator
AU2003268386A1 (en) Controlled drug release tablets
AU2003211586A1 (en) Drugs containing riboflavin-type compounds
AU2002241758A1 (en) Drug screening system
AU2003281049A1 (en) Detection of prion disease
AU2002333276A1 (en) Drugs for vasculopaties
AU2002367863A1 (en) Methods for sterilizing biological materials
AU2003289084A1 (en) Dispencer for coin or its kind
AU2002352265A1 (en) Automatic medicament dispenser for pharmacies
AU2003296568A1 (en) Portioned products comprising different constituents
AU2003220919A1 (en) Drugs for increasing lacrimal fluid
AU2002953022A0 (en) Screening device

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase